Education
About Us
Working with TipRanks
Follow Us
HeartBeam (BEAT)
NASDAQ:BEAT
BEAT Stock Chart & Stats
$2.56
$0.00(0.00%)
At close: 4:00 PM EST
$2.56
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.54 - $4.00
Previous CloseN/A
Volume12.23K
Average Volume (3M)89.04K
Market Cap
$49.94M
Enterprise Value$48.09M
Total Cash (Recent Filing)$1.86M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Mar 19, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding34,443,560
10 Day Avg. Volume76,817
30 Day Avg. Volume89,039
Financial Highlights & Ratios
PEG Ratio-2.27
Price to Book (P/B)37.05
Price to Sales (P/S)0.00
P/FCF Ratio-4.18
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.01K
Enterprise Value/Ebitda-2.32
Forecast
1Y Price Target
$5.83Price Target Upside127.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical PerformanceClinical study results demonstrating strong diagnostic agreement with standard 12-lead ECGs support confidence in device accuracy for arrhythmia assessment and can drive physician adoption.
Commercial PartnershipsA nationwide reader partnership with HeartNexus supplies 24/7 cardiology review capacity, enabling scalable interpretation services and recurring revenue opportunities from remote monitoring.
Regulatory ClearanceFDA 510(k) clearance for the 12-lead ECG synthesis software provides regulatory validation that supports clinical acceptance and enables a pilot commercial rollout.
Bears Say
Adoption And Reimbursement ChallengesReimbursement uncertainty and potential competitive pressures may slow uptake in target concierge and preventive cardiology markets, reducing near-term revenue visibility.
Financing RiskLimited cash runway and reliance on interim financing increase the likelihood of a dilutive capital raise or operational strain if regulatory milestones are delayed.
Regulatory UncertaintyA Not Substantially Equivalent outcome for a 510(k) submission creates regulatory uncertainty that could delay additional clearances and slow broader commercialization plans.
HeartBeam News
BEAT FAQ
What was HeartBeam’s price range in the past 12 months?
HeartBeam lowest stock price was $0.54 and its highest was $4.00 in the past 12 months.
What is HeartBeam’s market cap?
HeartBeam’s market cap is $49.94M.
When is HeartBeam’s upcoming earnings report date?
HeartBeam’s upcoming earnings report date is Mar 19, 2026 which is in 44 days.
How were HeartBeam’s earnings last quarter?
HeartBeam released its earnings results on Nov 13, 2025. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.129 by -$0.021.
Is HeartBeam overvalued?
According to Wall Street analysts HeartBeam’s price is currently Undervalued.
Does HeartBeam pay dividends?
HeartBeam does not currently pay dividends.
What is HeartBeam’s EPS estimate?
HeartBeam’s EPS estimate is -0.14.
How many shares outstanding does HeartBeam have?
HeartBeam has 34,443,560 shares outstanding.
What happened to HeartBeam’s price movement after its last earnings report?
HeartBeam reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.129. Following the earnings report the stock price went down -0.637%.
Which hedge fund is a major shareholder of HeartBeam?
Currently, no hedge funds are holding shares in BEAT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HeartBeam Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.83 (127.86% Upside)
$5.83 (127.86% Upside)
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.97%
12-Months-Change
Fundamentals
Return on Equity
-792.01%
Trailing 12-Months
Asset Growth
-40.93%
Trailing 12-Months
Company Description
HeartBeam
HeartBeam, Inc., a medical technology company, primarily focuses on telemedicine solutions for the detection and monitoring of cardiac disease outside a healthcare facility setting. The company also focuses on providing diagnostic data to physicians with care management of patients with cardiovascular disease. Its telehealth product comprises a credit card sized electrocardiogram machine and a cloud-based diagnostic software system to address the rapidly growing field of remote patient monitoring. The company was incorporated in 2015 and is headquartered in Santa Clara, California.
BEAT Company Deck
BEAT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress towards FDA clearance and commercial readiness, including strategic partnerships and successful clinical trials. However, the tight cash position and dependence on the FDA clearance present notable challenges.View all BEAT earnings summariesBEAT Stock 12 Month Forecast
Average Price Target
$5.83
▲(127.86% Upside)
Technical Analysis
Ownership Overview
13.81% Insiders
3.40% Mutual Funds
<0.01% Other Institutional Investors
79.91% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---